AVEO Pharmaceuticals, Inc.
AVEO
AVEO was delisted on the 19th of January, 2023.
48 hedge funds and large institutions have $18.8M invested in AVEO Pharmaceuticals, Inc. in 2015 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 11 increasing their positions, 16 reducing their positions, and 7 closing their positions.
100% more call options, than puts
Call options by funds: $108K | Put options by funds: $54K
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
11% less funds holding
Funds holding: 54 → 48 (-6)
31% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 16
36% less capital invested
Capital invested by funds: $29.6M → $18.8M (-$10.8M)
86% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$144K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$76K |
| 3 |
RCM
Rotella Capital Management
Bellevue,
Washington
|
+$15.2K |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$14.5K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$12.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
PointState Capital
New York
|
-$1.04M |
| 2 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
-$469K |
| 3 |
SIM
Spark Investment Management
New York
|
-$211K |
| 4 |
Creative Planning
Overland Park,
Kansas
|
-$167K |
| 5 |
Two Sigma Investments
New York
|
-$163K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ISL
51
Ingalls & Snyder LLC
New York
| – | -$26K | -1,539 | Closed |
|
52
Simplex Trading
Chicago,
Illinois
| – | -$4.96K | -343 | Closed |
|
53
Citigroup
New York
| – | -$1K | -36 | Closed |
|
AVEO Hedge Fund Activity: Q3 2015 in Review
48 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in AVEO Pharmaceuticals, Inc. (AVEO) for Q3 2015, worth a combined $18.8M — down 36% from $29.6M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of AVEO and 1 opened new positions — a net loss of 6 holders — while 16 trimmed existing stakes and 11 added.
The largest buyer was Vanguard Group, adding an estimated $144K. The largest seller was PointState Capital, exiting entirely with an estimated $1.04M sold.
- 48 institutional investors held AVEO Pharmaceuticals, Inc. (AVEO) as of Q3 2015, down from 54 in Q2 2015.
- Funds reported $18.8M of AVEO Pharmaceuticals, Inc. stock for Q3 2015, down 36% quarter-over-quarter.
- 1 fund opened new AVEO Pharmaceuticals, Inc. positions in Q3 2015 and 7 closed out, a net change of -6 holders.
- The largest AVEO Pharmaceuticals, Inc. buyer in Q3 2015 was Vanguard Group, an estimated $144K added.
- The largest AVEO Pharmaceuticals, Inc. seller in Q3 2015 was PointState Capital, an estimated $1.04M sold.
Based on aggregated 13F filings for Q3 2015.